Pharmacokinetic Analysis and Antiepileptic Activity of N-valproyl Derivatives of GABA and Glycine

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 1995 Jun 1

PMID 7667199

Citations 6

Authors

S Hadad

M Bialer

Affiliations

Soon will be listed here.

Abstract

Purpose: To explore the possibility of utilizing valproyl derivatives of GABA and glycine as new antiepileptics by using the structure pharmacokinetic-pharmacodynamic relationship (SPPR) approach.

Methods: The pharmacokinetics and pharmacodynamics (anticonvulsant activity and neurotoxicity) of the following four conjugation products of valproic acid (VPA), glycine and GABA were investigated: valproyl glycine, valproyl glycinamide, valproyl GABA and valproyl gabamide.

Results: Only valproyl glycinamide showed a good anticonvulsant profile in both mice and rats due to its better pharmacokinetic profile. Valproyl glycinamide was more potent than one of the major antiepileptic agents--VPA and showed a better margin between activity and neurotoxicity. Valproyl glycine and valproyl GABA were partially excreted unchanged in the urine (fe = 50% and 34%, respectively), while the urinary metabolites of the amide derivatives were valproyl glycine and valproyl GABA.

Conclusions: The four investigated valproyl derivatives did not operate as chemical drug delivery systems (CDDS) of glycine or GABA, but acted rather as drugs on their own. The current study demonstrates the benefit of the SPPR approach in developing and selecting a potent antiepileptic compound in intact animals based not only on its intrinsic pharmacodynamic activity, but also on its better pharmacokinetic profile.

Citing Articles

Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?.

Gerlach A, Krajewski J Pharmaceuticals (Basel). 2016; 3(9):2884-2899.

PMID: 27713381 PMC: 4034102. DOI: 10.3390/ph3092884.

Valproic Acid: second generation.

Bialer M, Yagen B Neurotherapeutics. 2007; 4(1):130-7.

PMID: 17199028 PMC: 7479693. DOI: 10.1016/j.nurt.2006.11.007.

Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice.

Isoherranen N, Yagen B, Spiegelstein O, Finnell R, Merriweather M, Woodhead J Br J Pharmacol. 2003; 139(4):755-64.

PMID: 12812999 PMC: 1573897. DOI: 10.1038/sj.bjp.0705301.

Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.

Spiegelstein O, Kroetz D, Levy R, Yagen B, Hurst S, Levi M Pharm Res. 2000; 17(2):216-21.

PMID: 10751038 DOI: 10.1023/a:1007577600088.

The disposition of valproyl glycinamide and valproyl glycine in rats.

Blotnik S, BERGMAN F, Bialer M Pharm Res. 1997; 14(7):873-8.

PMID: 9244143 DOI: 10.1023/a:1012143631873.

References

Granneman G, Wang S, MACHINIST J, Kesterson J . Aspects of the metabolism of valproic acid. Xenobiotica. 1984; 14(5):375-87. DOI: 10.3109/00498258409151426. View

Seiler N, Sarhan S . Synergistic anticonvulsant effects of a GABA agonist and glycine. Gen Pharmacol. 1984; 15(4):367-9. DOI: 10.1016/0306-3623(84)90018-1. View

Taylor C, Vartanian M, Yuen P, Bigge C, Hill D . Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 1993; 14(1):11-5. DOI: 10.1016/0920-1211(93)90070-n. View

Yamaoka K, Nakagawa T, Uno T . Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978; 6(6):547-58. DOI: 10.1007/BF01062109. View

OBrien E, Tipton K, Strolin Benedetti M, Bonsignori A, Marrari P, Dostert P . Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?. Biochem Pharmacol. 1991; 41(11):1731-7. DOI: 10.1016/0006-2952(91)90177-7. View

Lambert D, Poupaert J, Maloteaux J, Dumont P . Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration. Neuroreport. 1994; 5(7):777-80. DOI: 10.1097/00001756-199403000-00010. View

Nau H, Hauck R, Ehlers K . Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol. 1991; 69(5):310-21. DOI: 10.1111/j.1600-0773.1991.tb01303.x. View

Porter R, Cereghino J, Gladding G, Hessie B, KUPFERBERG H, SCOVILLE B . Antiepileptic Drug Development Program. Cleve Clin Q. 1984; 51(2):293-305. DOI: 10.3949/ccjm.51.2.293. View

Hammond E, Wilder B . Gamma-vinyl GABA: a new antiepileptic drug. Clin Neuropharmacol. 1985; 8(1):1-12. DOI: 10.1097/00002826-198503000-00001. View

10.

Grant S, Heel R . Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991; 41(6):889-926. DOI: 10.2165/00003495-199141060-00007. View

11.

Wood J, Krogsgaard-Larsen P, Schousboe A . Amplification by glycine of the effect of the GABA transport inhibitor THPO on synaptosomal GABA level. Neurochem Res. 1988; 13(10):917-21. DOI: 10.1007/BF00970762. View

12.

Liu Z, Seiler N, Marescaux C, Depaulis A, VERGNES M . Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine. Eur J Pharmacol. 1990; 182(1):109-15. DOI: 10.1016/0014-2999(90)90498-u. View

13.

Silverman R, Andruszkiewicz R, Nanavati S, Taylor C, Vartanian M . 3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase. J Med Chem. 1991; 34(7):2295-8. DOI: 10.1021/jm00111a053. View

14.

Vamvakides A, Kolokouris N . [Synergic effect of GABA and glycine in the antagonism of convulsions caused by pentetrazole in rats. Study of glycine valproamide]. Ann Pharm Fr. 1986; 44(6):501-8. View

15.

Bialer M, Friedman M, Rubinstein A . Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma. J Pharm Sci. 1984; 73(7):991-3. DOI: 10.1002/jps.2600730734. View

16.

Zaccara G, Messori A, Moroni F . Clinical pharmacokinetics of valproic acid--1988. Clin Pharmacokinet. 1988; 15(6):367-89. DOI: 10.2165/00003088-198815060-00002. View

17.

Toth E, Lajtha A . Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem Res. 1984; 9(12):1711-8. DOI: 10.1007/BF00968081. View

18.

Vamvakides A . [Synthesis and pharmacological study of glycine linoleamide]. Ann Pharm Fr. 1986; 44(2):145-55. View

19.

Benet L, Galeazzi R . Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979; 68(8):1071-4. DOI: 10.1002/jps.2600680845. View